AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
July 27, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022